In Reply We thank Marzano et al for their interest in our article1 and agree that understanding the background risk of venous thrombotic events (VTEs) in chronic inflammatory skin diseases (CISDs) is critical. The CISDs selected for this initial study were among the more common and currently have multiple clinical trials assessing Janus kinase (JAK) inhibitors, a target potentially associated with VTE risk, for these indications. Future studies are under way to investigate VTE risk in very rare CISDs that affect different patient populations, such as bullous pemphigoid. We agree there is differential risk between dermatologic conditions, and it is critical not to extrapolate the results from 1 set of patients to another.
Schneeweiss MC, Silverberg JI, Mostaghimi A. Venous Thromboembolism in Chronic Inflammatory Skin Diseases—The Need to Consider Bullous Pemphigoid—Reply. JAMA Dermatol. 2022;158(3):331–332. doi:10.1001/jamadermatol.2021.3828
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.